The value of the global biosimilars market is predicted to exceed $457 billion by 2027. COVID-19 and its economic impacts have only strengthened the rationale for the development of a strong biosimilar market as health systems seek to reduce costs and make the most advanced treatments available to wider sections of the global population.

At Cromos Pharma, we have extensive expertise in managing clinical trials for biosimilars by facilitating efficient and effective patient recruitment and retention across our operations in Eastern Europe and CIS Region. We are also experienced in design and management of the initial Phase I studies in healthy volunteers and can offer Cromos-coordinated support of our preferred biosimilar partners, uniquely experienced Phase I units in EU, US and Australia.

Email bd@cromospharma.com or visit www.cromospharma.com for more information.

свернуть